John G Ullman & Associates Inc. Trims Holdings in IQVIA Holdings Inc. (NYSE:IQV)

John G Ullman & Associates Inc. trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,900 shares of the medical research company’s stock after selling 200 shares during the quarter. John G Ullman & Associates Inc.’s holdings in IQVIA were worth $373,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of IQV. FMR LLC raised its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA during the third quarter worth about $147,683,000. JPMorgan Chase & Co. grew its holdings in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Nordea Investment Management AB grew its holdings in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the period. Finally, KBC Group NV grew its holdings in IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after acquiring an additional 250,458 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on IQV shares. Bank of America dropped their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Truist Financial reaffirmed a “buy” rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Leerink Partners reissued an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Finally, UBS Group dropped their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $188.89 on Monday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The business’s 50 day moving average price is $199.13 and its 200-day moving average price is $214.65. The firm has a market capitalization of $33.26 billion, a PE ratio of 25.19, a P/E/G ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 1 year low of $184.66 and a 1 year high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.